Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 1-Year Low - Here's Why

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $54.95 and last traded at $54.95, with a volume of 350 shares changing hands. The stock had previously closed at $56.11.

Wall Street Analysts Forecast Growth

Separately, William Blair raised shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Stock Performance

The company has a market cap of $4.10 billion, a price-to-earnings ratio of -23.18 and a beta of 0.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The firm has a fifty day simple moving average of $65.35 and a 200 day simple moving average of $81.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10. The firm had revenue of $1.14 million during the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. On average, sell-side analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.